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Abstract
The etiologic link between H. pylori infection and gastric chronic inflamma-
tion and related complications has been well established, but pathogenic pathways 
are still widely discussed and not sufficiently clear. The introduction of culture-
independent molecular techniques has allowed better understanding of the gastric 
microbiota and has revealed that, when present, H. pylori represents the main 
colonizer but is part of a far more complex and dynamic microbiota than previ-
ously thought. This conceptual shift has made way for new pathogenic theories, 
focused on the interrelations between H. pylori and other gastric microbiota. Main 
factors that affect the gastric microbiota are gastric acidity, inflammation, and 
environmental factors, such as diet and drugs. Previous studies have made progress 
in explaining the complex interactions between gastric microorganisms in healthy 
individuals and their role in the development of related gastroduodenal (peptic 
ulcers and gastric cancer (GC)) and extraintestinal diseases, but more scientific 
proof is needed. This review presents current knowledge on gastric microbiota and 
its role in health and in the development of gastroduodenal diseases.
Keywords: gastric microbiota, H. pylori, pathogenesis, chronic inflammation,  
peptic ulcers, gastric cancer
1. Introduction
The first isolation of Helicobacter pylori (H. pylori) in 1982 [1] changed the tradi-
tional misconception that the stomach, with its naturally hostile environment, can-
not be a reservoir for microbial species. Since then H. pylori has been well established 
as a key factor in gastric pathology, being the main cause of chronic active gastritis. 
This inflammation can progress to often interlinked severe complications such as 
atrophic gastritis, peptic ulcer disease, and gastric malignancies [2]. The assumption 
of the uniqueness of H. pylori as the only bacteria able to survive in the gastric hostile 
environment has also fast been shattered with the advances in culture-dependent 
and culture-independent techniques that revealed that H. pylori is part of a complex 
gastric microbiota. The gastric microbial density is now estimated at around 102 to 
104 colony-forming units (CFU)/mL [3], with variations related to local pH, site of 
isolation, and environmental factors, such as food ingestion and medication intake. 
Furthermore, the pool of species and subspecies varies related to H. pylori status and 
related pathologic complications. Due to this multitude of factors, the differentiation 
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between resident and transient microbiota and its role in health and disease remains 
controversial. Nevertheless, the potential of understanding the structure and 
dynamics of the gastric microbiota for the pathogenesis, diagnosis, and treatment 
of gastroduodenal diseases remains. Hence, this review aims to underline current 
knowledge on gastric microbiota and its relation to gastroduodenal pathology.
2. The hostile gastric environment
Compared to other gastrointestinal (GI) segments, the stomach has a physi-
ological environment that is significantly more hostile to bacterial colonization 
and is a crucial part of the dynamics of the gastric microbiota. Primary reason for 
this is the gastric juice, which is composed of two main components—proteolytic 
enzymes and hydrochloric acid (HCl). The hydrochloric acid creates a strong acidic 
environment by maintaining a pH of 1–2 in the gastric lumen, which together with 
the proteolytic features of the gastric enzymes creates an intragastric environment 
that serves both digestive and protective roles. This environment facilitates the 
denaturation of proteins and nutrient absorption but also severely limits bacterial 
colonization and survival, preventing infection by pathogens [4]. The low pH value 
is the main restrictive component of the gastric juice [5]. To prevent damage to the 
mucosa from the acid and enzymes, neck cells of the gastric glands secrete mucus 
on the surface of the gastric epithelium. This mucus layer establishes a pH gradient 
that increases the pH up to 6–7 at the surface of the mucosa [6]. This is due to the 
unique properties of the mucus which permit acid to flow from parietal cells into 
crypts which communicate with the lumen, but do not allow acid at pH <4 from 
penetrating the mucus layer [6]. The mucus layer consists of several different mucin 
molecules, including MUC1, MUC5AC, MUC5AB, and MUC6, and forms two 
sublayers, an inner mucus layer that is firmly attached to the epithelia and a loose 
mucus layer, which is in direct contact with the lumen [7, 8]. Additional factors that 
contribute to the strong antimicrobial environment of the stomach are the acciden-
tal bile reflux and the gastric peristalsis.
3. H. pylori
In 1982 Helicobacter pylori was isolated by Barry Marshall and Robin Warren [1]. 
Their research changed the long-standing view that the stomach is as a sterile organ, 
being naturally hostile to bacterial survival. Today, it is known that H. pylori infects 
more than 50% of the world’s population with the only significant reservoir for the 
infection appearing to be humans. Possible routes of infection include oral-oral, 
fecal-oral, and iatrogenic spread (e.g., by unsterile endoscopic interventions). In 
developing countries, infection is usually acquired early in childhood, unlike in 
industrialized countries, where it develops more commonly in adulthood [9].
H. pylori is a Gram-negative, spiral-shaped, motile, and flagellated bacteria that 
is uniquely adapted to colonizing the gastric niche. Hence, it comes with no surprise 
that when present, H. pylori has the highest relative abundance among all gastric 
microbial communities in both adults and children [10–12]. Upon infection, H. 
pylori utilizes urease and α-carbonic anhydrase to generate ammonia and HCO3
−. 
This neutralizes H+ and locally increases the pH, facilitating the bacteria’s passage 
through the acidic gastric fluid and the pH-sensitive mucous layer. Using chemo-
taxis, the bacteria navigates the pH gradient to their niche near the host’s epithelium 
[13, 14]. Once established in the inner mucus layer, H. pylori can utilize diverse 
adhesins (e.g., SabA and BabA) to attach to epithelial cells. Once attached, bacterial 
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effector molecules, such as the vacuolating cytotoxin (VacA) and the cytotoxin-asso-
ciated gene A (CagA), modulate the gastric epithelial cell behavior, leading to loss of 
cell polarity, release of nutrients and chemokines, and regulation of acid secretion 
via control of gastrin and H+/K+ ATPase [9, 15, 16]. In response to the H. pylori 
infection, the host mounts a complex inflammatory response, which ultimately leads 
to active chronic gastritis and subsequent gastroduodenal diseases. Therefore, the 
host’s attempts to eradicate H. pylori increase gastric immunopathology (gastritis, 
epithelial damage such as atrophy and intestinal metaplasia), which alters the gastric 
compartment and its microbiota and may subsequently progress to gastric cancer.
4. Other non-H. pylori microbiota
4.1 Culture-dependent identification of gastric microbiota
Initial studies on the bacteria present in the stomach, using culture-based 
techniques, such as gastric juice cultures and mucosal biopsies were reported even 
before the isolation of H. pylori. In 1977 Savage DC [17] isolated bacteria from the 
stomach estimated at >103 CFU/g. The predominant phyla were Firmicutes (genera 
Lactobacillus, Streptococcus, Clostridium, and Veillonella), Actinobacteria (genus 
Bifidobacterium), and Proteobacteria (coliforms). However, due to the fact that these 
bacteria are prevalent along the whole GI tract, they were considered transient bac-
teria, which form small colonies that exist for short periods of time, rather than true 
gastric colonizers. Later culture-based studies [18–23] find that the most prevalent 
phylum, regardless of H. pylori status, is Firmicutes, followed by Proteobacteria and 
Bacteroidetes. Actinobacteria varies in studies as the second or third most prevalent 
phylum. The most commonly found genera were Streptococcus, Lactobacillus, 
Bacteroides, Staphylococcus, Veillonella, Corynebacterium, and Neisseria. However, 
given that culturing conditions for the majority of microbes colonizing the GI tract 
are not established, culture-based methods are considered to underestimate the gas-
tric microbial diversity and are largely replaced by culture-independent methods.
4.2 Culture-independent identification of gastric microbiota
Culture-independent studies use a variety of molecular methods based on 16S 
rRNA gene sequencing. A multitude of reasons define these methods as far superior 
to those which are culture-dependent. These include:
• 16S rRNA is present in almost all bacteria.
• The function of the 16S rRNA gene has remained unchanged over time, sug-
gesting that random sequence changes are a more accurate measure of time 
(evolution).
• The 16S rRNA gene is large enough for computational purposes [24].
A variety of 16S rRNA based methods exist, including:
• Fluorescent in situ hybridization (FISH) [25]
• Dot-blot hybridization with rRNA-targeted probes [26]
• Targeted qPCR [27]
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• Traditional or sequence-aided community fingerprinting [28]
• Temperature gradient gel electrophoresis (TGGE) [29]
• Terminal restriction fragment length polymorphism (T-RFLP) [30]
• Sequencing of cloned 16S rDNA [29]
• Microarrays (PhyloChip) [31]
• Next-generation sequencing (NGS) [32]
In an extensive review of eight culture-independent studies, Sheh A. and Fox 
J. concluded that the most prominent phyla in the stomach are Proteobacteria, 
Firmicutes, Bacteroidetes, Actinobacteria, and Fusobacteria [33]. Furthermore, the 
most abundant phyla in H. pylori-positive subjects are Proteobacteria, Firmicutes, 
and Actinobacteria. In the absence of H. pylori, the most abundant phyla are 
Firmicutes, Bacteroidetes, and Actinobacteria. However, H. pylori remains the most 
dominant species in the stomach, comprising 72–99% of sequencing reads [10, 34]. 
In the absence of H. pylori, analysis consistently shows the presence of Streptococcus 
spp., which seem to be the most abundant genus in H. pylori-negative subjects 
[3, 30, 35, 36]. In the gastric microbiota, the non-Helicobacter genera commonly 
detected are Streptococcus, Prevotella, Veillonella, and Rothia.
5. Interrelations between H. pylori and other gastric microbiota
Numerous studies have shown significant variability of the gastric microbial 
communities with respect to H. pylori status. One such study was carried out 
by Osaki et al. [37], who examined the gastric microbiota of H. pylori-positive 
and H. pylori-negative Mongolian gerbils. The study showed a larger number 
of Bifidobacterium spp. in H. pylori-positive gerbils, compared to the H. pylori-
negative, while Eubacterium cylindroides and Prevotella spp. were only found in the 
H. pylori-negative group.
Several mouse model studies have also shown clear differences in the composi-
tion of the gastric microbiota with respect to H. pylori status. Infection by H. pylori 
of pathogen-free female BALB/c mice has been shown to reduce the Lactobacillus 
spp. in the gastric microflora [26]. In transgenic, insulin-gastrin (INS-GAS) mice, 
the H. pylori-infected male mice show a significantly different phyla compared to 
the non-infected control group, with an increase in Firmicutes and a decrease in 
Bacteroidetes [26]. Findings in H. pylori-colonized C57BL/6 N female mice included 
reductions in Firmicutes (class Bacilli), Bacteroidetes, and Proteobacteria and an 
increase of Firmicutes (class Clostridia), Proteobacteria (genus Helicobacter), and 
Verrucomicrobia. However, other published data on the murine gastric microbiota 
suggest that neither acute nor chronic H. pylori infection substantially modifies the 
gastric microbial ecosystem [38].
A few studies have also examined H. pylori-related microbial differences in humans. 
One study found relative abundances of Proteobacteria, Spirochetes, and Acidobacteria in 
H. pylori-positive patients, compared to the control H. pylori-negative group. Another 
study demonstrated that patients positive for H. pylori culture showed significantly 
increased colonization of Proteobacteria and a decrease in Actinobacteria [39].
A few studies have given insight on how other microbial species can affect H. pylori 
by modulating H. pylori-induced gastric inflammatory responses. Two studies have 
5Gastric Microbiota: Between Health and Disease
DOI: http://dx.doi.org/10.5772/intechopen.86926
indicated that the presence of intestinal Helicobacter (H. bilis, H. hepaticus, and H. 
muridarum) can both increase and decrease the severity of H. pylori-induced gastric 
inflammation by altering Treg cell responses [40, 41]. Another study demonstrated that 
H. pylori is present within the intestine in a coccoid form and that its interaction with 
phagocytes within the intestinal Peyer’s patches modifies the intensity of H. pylori-
induced gastritis [42]. However, other studies have shown that the gastric microbiota 
can accelerate gastric cancer progression in the presence of H. pylori and does so with no 
differences detected in the composition of the intestinal microbiota [27, 32].
As previously described H. pylori infection is associated with a multitude of 
changes in the gastric physiology and immunology, e.g., reduced gastric acidity, dis-
turbed nutrient availability, and local inflammatory responses. These changes might be 
one explanation for the shift in the gastric microbial communities described, but the 
relation between H. pylori and non-H. pylori microbiota seems to be far more complex 
and remains to be further clarified. One problem is that so far, most studies are focused 
only on the effects of H. pylori on other microbiota, but little is known of how H. pylori 
is affected by other resident bacteria. Another problem is that different studies cannot 
be objectively compared, since they highly vary in methods and models used and the 
results depend on numerous other factors such as the time of H. pylori infection and 
the degree of mucosal inflammation. Therefore, further experiments are needed to 
give a more extensive understanding of these complex microbial interrelations.
6. Factors affecting the gastric microbiota
As described, H. pylori is the most significant species that colonizes the stomach 
and a key factor for the gastric microbial diversity but is far from sufficient to provide 
a wholesome understanding of the factors that determine its dynamics. Major factors 
that influence and define the dynamics of the gastric microbiota include gastric acid-
ity, inflammation of the gastric mucosa, dietary habits, and use of medications.
6.1 Gastric acidity
The human gastric juice has an interprandial pH of between 1 and 2 in the gastric 
lumen, whereas with food ingestion it can reach up to pH 5. pH also varies in the 
different anatomical regions of the stomach, with most acidic being the fundus and 
the least being the antrum. The mucus lining the gastric mucosa establishes also a pH 
gradient from the lumen to the surface of the epithelium. This mucus consists of two 
sublayers—an inner mucus layer that is firmly attached to the epithelium and a vari-
able mucus layer directly interacting with the lumen [7, 8]. Thus, across the mucus 
layer, the pH ranges from about 5.5 to 6.8 or even 7 at the surface of the gastric epi-
thelial cells [5, 6]. It was already discussed that the low pH, caused by the hydrochlo-
ric acid, restricts the quantity of microorganisms and reduces the risk of infection by 
pathogens. Hence, sites with higher pH are significantly more hospitable to coloniza-
tion and have a higher microbial density. Considerable fluctuations in the microbial 
density have been described with respect to the pH in the stomach, whereby both the 
quantity and the proportion of genera also fluctuate [43, 44]. Bacteria and bacterial 
DNA, which are isolated from gastric juice, differ from bacterial isolates adhering to 
the mucosa. During abnormal conditions, this balance may be different.
6.2 Dietary habits
While many studies document the effects of diet on the gut microbiota com-
position in humans, [45–49] there are only a few, mainly animal model studies, 
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addressing the influence of diet on the gastric microbiota. An example is an in vivo 
study that compared the gastric microbiota of mice fed a non-purified diet (natural 
source-derived food) to mice fed a purified diet (refined food) and found higher 
levels of total aerobes, total anaerobes, and Lactobacillus in the stomach of the mice 
on a non-purified diet [50]. Nevertheless, it is well established how dietary factors 
affect the gastric microclimate, and since the microbiota is an inseparable part of 
this microclimate, it is not farfetched to suspect that diet affects the gastric micro-
bial communities. However, more research is needed.
6.3 Use of medications
The long-term use of proton pump inhibitors (PPIs) and H2 antagonists affects 
the composition of the gastric microbiota by inducing a non-H. pylori bacterial 
overgrowth [51]. This is not surprising, considering that normally the non-H. pylori 
gastric microbiota is suppressed by the significantly acidic gastric environment. 
Suppression of gastric acidity will alter the bacterial flora of the upper GI tract, and 
studies have confirmed that PPIs do alter the bacterial population in the stomach [52]. 
This is mainly due to oral bacteria that survive instead of being killed in the normally 
acidic stomach. It has also been suspected that by causing alteration and overgrowth 
of the microbiota, acid-suppressive treatments may increase the risk of gastric cancer 
[52]. It has also been shown that a previously antrum-dominant H. pylori infection 
after treatment with acid inhibitors changed to a more corpus predominant infec-
tion [51]. The less acidic corpus allows H. pylori to penetrate deeper in the crypts and 
increase the inflammation, which causes faster progression to atrophy [53]. Treatment 
with acid inhibitors has by culture-dependent methods been shown to affect the sur-
vival of bacteria in the stomach. However, no significant differences have been found 
regarding diversity and composition of the microbiota by using culture methods [10].
Antibiotics are well known to have suppressive effects on the gastrointestinal 
microflora. H. pylori eradication is dependent on combined antibiotic treatment. 
However, certain antibiotic treatments can have negative effects on the “healthy” 
gastric microbiota. Animal studies indicate that treatment with penicillins reduces 
Lactobacillus populations and promotes yeast colonization of the gastric epithelium. 
Furthermore, Mason et al. [54] showed that cefoperazone treatment in humans 
causes long-term alteration of the gastric microbiota, such as a significant reduction 
in the number of Lactobacillus and overgrowth of Enterococcus.
7. Gastric microbiota and gastroduodenal diseases
7.1 Chronic gastritis and peptic ulcer disease
The isolation of H. pylori was a real breakthrough, not because it declared the 
stomach as a non-sterile organ but because subsequent research established it as a 
main etiological factor for the development of gastroduodenal diseases [2, 55, 56]. 
It is well known that long-term H. pylori infection causes various degrees of chronic 
inflammation of the underlying gastric mucosa. A subset of patients develops clinical 
symptoms, and a further subset will develop complications including peptic ulcer, 
gastric mucosa-associated lymphoid tissue (MALT) lymphoma, and gastric cancer. 
The cascade leading from chronic gastritis to neoplasm is known as Correa’s cascade 
and involves the progression to glandular atrophy with intestinal metaplasia and 
dysplasia and eventually to invasive carcinoma [57]. Peptic ulcer disease is the most 
common complication of chronic H. pylori infection, with 95% of duodenal and 
70% of gastric ulcers being linked to it [58]. All of this serves to prove that H. pylori 
7Gastric Microbiota: Between Health and Disease
DOI: http://dx.doi.org/10.5772/intechopen.86926
is by far the most important microbial species that can colonize the stomach, with an 
enormous impact on the pathogenesis and development of gastroduodenal diseases.
Nevertheless, there is arising evidence that non-H. pylori bacteria may also play an 
important role in the pathogenesis of chronic gastritis and peptic ulcers. One study sug-
gests that different gastric microbial communities, such as the overrepresentation of the 
Streptococcus genus within the Firmicutes phylum, can lead to gastritis as well, even in 
the absence of H. pylori [35]. Another study has found an increase of Streptococcus and 
a decrease of Prevotella in patients with atrophic gastritis, versus healthy subjects [59]. 
There are also several studies that assess the role of non-H. pylori species in peptic ulcer 
disease. The non-H. pylori bacteria seems to be more prevalent in patients with non-
ulcer dyspepsia than in those with gastric ulcer as shown by a culture-based study by Hu 
et al. [19]. Another study in Malaysian patients showed significant correlation between 
the isolation of Streptococcus and patients with peptic ulcers [60]. Given that most stud-
ies find that the Streptococcus genus is one of the most abundant non-H. pylori species 
in the stomach, a possible pathogenic relation can be a subject of further research. 
However, by far no other species have an established pathogenic role except H. pylori.
7.2 Gastric cancer
Each year approximately 990,000 people are diagnosed with gastric cancer 
(GC) worldwide, of whom about 738,000 die from this disease, making GC the 
fourth most common incident cancer and the second most common cause of cancer 
death. Both incidence and mortality rates are about twice as high in males as in 
females. Over 70% of cases occur in developing nations, concentrated in Eastern 
Asia, Eastern Europe, and Central and South America. Approximately 90% of 
gastric cancers are adenocarcinomas, with the other 10% shared between mucosa-
associated lymphoid tissue (MALT) lymphomas, gastrointestinal stromal tumors 
(GIST), leiomyosarcomas, and other more rare types of cancer. Adenocarcinomas 
are histologically classified into two major types: diffuse and intestinal. These two 
types not only look different under the microscope but also differ in gender ratio, 
age at diagnosis, and other epidemiologic features. Anatomically, gastric cancers are 
categorized as proximal and distal. Proximal adenocarcinomas are more similar to 
esophageal adenocarcinomas and may be associated with the absence of H. pylori, 
while distal adenocarcinomas originate in the antrum, with approximately 90% of 
such cases related to H. pylori infection [61]. Today the correlation between H. pylori 
and the development of gastric cancer is undeniable as shown in several prospective 
studies [62–64]. Moreover, the eradication of H. pylori is proven to significantly 
reduce the risk of gastric cancer development, according to several international 
consensuses [65, 66]. H. pylori was recognized as a “definite carcinogen” by the 
World Health Organization in 1994, and this fact was reconfirmed in 2009.
However, H. pylori coevolved with humans for millennia, and only 1–2% of 
people infected with this bacterium actually develop gastric cancer or MALT 
lymphoma. Similar to most cancers, pathogenetic mechanisms remain unclear with 
a multitude of other factors to influence the final carcinogenesis [61]. Although, 
H. pylori is clearly the most relevant microbial risk factor for the development of 
gastric cancer, an increasing pool of evidence suggests that other microbial commu-
nities play a causative role in the pathophysiology of gastric cancer. To date, several 
animal and human studies have supported this theory.
Studies with INS-GAS mice have revealed that male mice with intestinal microbiota 
developed gastric pathology from chronic gastritis to atrophy and dysplasia inde-
pendent of H. pylori infection. Furthermore, the presence of commensal microbiota 
accelerated the progression to gastric intraepithelial neoplasia, and gastric intraepithe-
lial neoplasia became invasive in H. pylori-infected INS-GAS mice. Male INS-GAS mice 
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with H. pylori infection, colonized with artificial mouse intestinal microbiota, have 
shown increased incidence of gastric intraepithelial neoplasia by 69% [27, 32]. On the 
other hand, antibiotic treatments significantly delayed the onset of gastric neoplasia in 
Helicobacter-free and specific pathogen-free INS-GAS mice [67].
A study by Wang et al. found a similar number of bacterial species in the 
microbiota between gastric cancer and chronic gastritis, but by using a method to 
explore and visualize similarities or dissimilarities of the data, a pattern suggesting 
the presence of a diversified microbiota in gastric cancer was found [68]. Moreover, 
a 16S rRNA gene sequencing analysis of gastric mucosa of patients with gastric 
cancer showed a prevalence of the genera Lactobacillus, Streptococcus (among which 
the most common species were S. mitis and Streptococcus parasanguinis), Prevotella, 
and Veillonella [30]. Two other studies evaluated the gastric microbiota of subjects 
with non-atrophic gastritis, intestinal metaplasia, and gastric cancer. The first 
one showed a significantly lower diversity and a higher abundance of the genus 
Pseudomonas in the microbiota of neoplastic patients compared to patients with 
simple gastritis. Moreover, both the progressive decrease of six taxa and the pro-
gressive increase of two taxa were observed from the gastritis group to the neoplas-
tic group, via the metaplastic group [69]. In the second study, a high-throughput 
sequencing platform was used for the assessment of gastric microbiota in the three 
groups, showing definitely different results: a greater bacterial diversity, a relative 
rise of Bacilli and Streptococcaceae, and a relative reduction of Helicobacteraceae were 
found in the cancer group compared to other groups [70].
It is possible that non-H. pylori species potentiate carcinogenesis through vari-
ous mechanisms, such as promoting inflammation, stimulating cell proliferation, 
modifying stem cell dynamics, and producing toxic metabolites [71]. However, it is 
still unsure whether the different microbial structure is causative for the carcino-
genesis or carcinogenesis itself causes a shift in the microbial communities, which 
subsequently promotes carcinogenesis further.
8. Gastric microbiota and extra-gastric diseases
The stomach is part of the GI tract, and as such, possible relations between the 
gastric microbiota’s composition and diseases of other parts of the GI tract, such as the 
esophagus (esophagitis and esophageal cancer), small intestines, and colon cannot be 
overlooked [72]. One study, using 16S rDNA analyses of duodenal aspirates, demon-
strated lower diversity in irritable bowel syndrome patients compared to controls with 
significant alterations in 12 genera [73]. An increased risk for colorectal neoplasia in H. 
pylori-infected patients has been confirmed by many large-scale studies [74, 75].
Other studies have addressed the association between autoimmune hepatitis and 
altered microbiome of the upper GI tract and found this to be linked to increased 
intestinal permeability [76].
Regarding the extra-gastrointestinal involvement of gastric microbiota (espe-
cially H. pylori), studies find possible associations with hematological diseases like 
idiopathic thrombocytopenic purpura [77] and anemia [78] and cardiovascular 
[79], neurological [80], and endocrine [81] diseases.
Nevertheless, research in this field is far from sufficient to be conclusive.
9. Discussion
It is undeniable that H. pylori is by far the most unique and important spe-
cies that can colonize the gastric niche with clear pathogenic significance to 
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gastroduodenal diseases. However, culture-dependent and later culture-indepen-
dent studies prove that the stomach harbors a complex microbiota with many other 
phyla (Proteobacteria, Firmicutes, Bacteroidetes, Actinobacteria, and Fusobacteria) 
and genera (Lactobacillus, Streptococcus, Clostridium, Prevotella, Veillonella, 
Bifidobacterium, and Rothia) being identified. By far, it is arguable which genera 
can be considered resident since results depend on a multitude of factors, among 
which gastric acidity stands out as the most significant. However, it is worth noting 
that Streptococcus, Prevotella, Veillonella, and Rothia seem to be the most abundant 
genera in H. pylori-negative subjects. Nevertheless, the significance of both tran-
sient and resident non-H. pylori microbiota lies in its possible role in the develop-
ment and progression of gastroduodenal diseases, such as gastritis, peptic ulcer 
disease, and gastric cancer. So far, only a few and far from enough studies suggest 
that non-H. pylori microbiota can lead to gastric pathology in the absence of H. 
pylori. However, findings are convincing that the non-H. pylori microbiota can play 
an important role in modulating H. pylori-induced gastric inflammation, influenc-
ing an individual’s risk of gastric diseases and consequently the severity of the 
resulting disease. Suspected pathophysiologic mechanisms involved in this include 
modulating immune cell responses, stimulating cell proliferation, modifying stem 
cell dynamics, and producing toxic metabolites. Although, substantial advance-
ments in unrevealing the complexity of the gastric microbiota and its’ role in health 
and disease have been made, studies are far from sufficient to suggest new strategies 
for prevention, diagnosis, and treatment of gastroduodenal diseases. However, this 
potential remains and undoubtedly should be further explored.
Acknowledgements
The publication of this work was supported by KRKA.
Conflict of interest
There are no conflicts of interest.
Gastrointestinal Stomas
10
Author details
Hristo Ilianov Iliev1*, Mila Dimitrova Kovacheva-Slavova2, Todor Asenov Angelov2, 
Hristo Yankov Valkov2, Ali Bedran3 and Borislav Georgiev Vladimirov2
1 Medical University—Sofia, Sofia, Bulgaria
2 Department of Gastroenterology, University Hospital “Tsaritsa Ioanna-ISUL”, 
Medical University of Sofia, Sofia, Bulgaria
3 Clinical Laboratory, University Hospital “Tsaritsa Ioanna-ISUL”, Sofia, Bulgaria, 
Medical University of Sofia, Sofia, Bulgaria
*Address all correspondence to: hilievbg@gmail.com
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
11
Gastric Microbiota: Between Health and Disease
DOI: http://dx.doi.org/10.5772/intechopen.86926
[1] Warren JR, Marshall BJ. Unidentified 
curved bacilli on gastric epithelium 
in active chronic gastritis. Lancet. 
1983;1:1273-1275. DOI: 10.1016/
S0140-6736(83)92719-8
[2] Wang F, Meng W, Wang B, Qiao L. 
Helicobacter pylori-induced gastric 
inflammation and gastric cancer. Cancer 
Letters. 2014;345(2):196-202. DOI: 
10.1016/j.canlet.2013.08.016
[3] Delgado S, Cabrera-Rubio R, Mira A, 
Suárez A, Mayo B. Microbiological 
survey of the human gastric ecosystem 
using culturing and pyrosequencing 
methods. Microbial Ecology. 
2013;65(3):763-772. DOI: 10.1007/
s00248-013-0192-5
[4] Martinsen TC, Bergh K, Waldum HL. 
Gastric juice: A barrier against 
infectious diseases. Basic & Clinical 
Pharmacology & Toxicology. 
2005;96:94-102. DOI: 10.1111/j.1742-
7843.2005.pto960202.x
[5] Manson JM, Rauch M, Gilmore MS. 
The commensal microbiology of 
the gastrointestinal tract. Advances 
in Experimental Medicine and 
Biology. 2008;635:15-28. DOI: 
10.1007/978-0-387-09550-9_2
[6] Bhaskar KR, Garik P, Turner BS, 
Bradley JD, Bansil R, Stanley HE, et al. 
Viscous fingering of HCl through gastric 
mucin. Nature. 1992;360:458-461. DOI: 
10.1038/360458a0
[7] Corfield AP, Carroll D, Myerscough N, 
Probert CS. Mucins in the 
gastrointestinal tract in health and 
disease. Frontiers in Bioscience. 
2001;6:D1321-D1357. DOI: 10.2741/
Corfield
[8] Atuma C, Strugala V, Allen A, 
Holm L. The adherent gastrointestinal 
mucus gel layer: Thickness and physical 
state in vivo. American Journal of 
Physiology. Gastrointestinal and Liver 
Physiology. 2001;280:G922-G929. DOI: 
10.1152/ajpgi.2001.280.5.G922
[9] Kusters JG, van Vliet AH, 
Kuipers EJ. Pathogenesis of Helicobacter 
pylori infection. Clinical Microbiology 
Reviews. 2006;19(3):449-490. DOI: 
10.1128/CMR.00054-05
[10] Bik EM, Eckburg PB, Gill SR, et al. 
Molecular analysis of the bacterial 
microbiota in the human stomach. 
Proceedings of the National Academy 
of Sciences of the United States of 
America. 2006;103(3):732-737. DOI: 
10.1073/pnas.0506655103
[11] Schulz C, Schütte K, Koch N, et al. 
The active bacterial assemblages of 
the upper GI tract in individuals with 
and without Helicobacter infection. 
Gut. 2016;67(2):216-225. DOI: 10.1136/
gutjnl-2016-312904
[12] Llorca L, Pérez-Pérez G, 
Urruzuno P, et al. Characterization of 
the gastric microbiota in a pediatric 
population according to Helicobacter 
pylori status. The Pediatric Infectious 
Disease Journal. 2017;36(2):173-178. 
DOI: 10.1097/INF.0000000000001383
[13] Williams SM, Chen YT, 
Andermann TM, Carter JE, McGee DJ, 
Ottemann KM. Helicobacter pylori 
chemotaxis modulates inflammation 
and bacterium-gastric epithelium 
interactions in infected mice. Infection 
and Immunity. 2007;75:3747-3757. DOI: 
10.1128/IAI.00082-07
[14] Croxen MA, Sisson G, Melano R, 
Hoffman PS. The Helicobacter pylori 
chemotaxis receptor TlpB 
(HP0103) is required for pH taxis 
and for colonization of the gastric 
mucosa. Journal of Bacteriology. 
2006;188:2656-2665. DOI: 10.1128/
JB.188.7.2656-2665.2006
References
Gastrointestinal Stomas
12
[15] Saha A, Backert S, Hammond CE, 
Gooz M, Smolka AJ. Helicobacter pylori 
CagL activates ADAM17 to induce 
repression of the gastric H, K-ATPase 
alpha subunit. Gastroenterology. 
2010;139:239-248. DOI: 10.1053/j.
gastro.2010.03.036
[16] O’Keeffe J, Moran AP. Conventional, 
regulatory, and unconventional 
T cells in the immunologic 
response to Helicobacter pylori. 
Helicobacter. 2008;13:1-19. DOI: 
10.1111/j.1523-5378.2008.00559.x
[17] Savage DC. Microbial ecology of the 
gastrointestinal tract. Annual Review 
of Microbiology. 1977;31:107-133. DOI: 
10.1146/annurev.mi.31.100177.000543
[18] Stockbruegger RW. Bacterial 
overgrowth as a consequence of 
reduced gastric acidity. Scandinavian 
Journal of Gastroenterology. 
Supplement. 1985;111:7-16. DOI: 
10.3109/00365528509093749
[19] Hu Y, He LH, Xiao D, Liu GD, 
Gu YX, Tao XX, et al. Bacterial flora 
concurrent with Helicobacter pylori in 
the stomach of patients with upper 
gastrointestinal diseases. World Journal 
of Gastroenterology. 2012;18:1257-1261. 
DOI: 10.3748/wjg.v18.i11.1257
[20] Zilberstein B, Quintanilha AG, 
Santos MA, Pajecki D, Moura EG, 
Alves PR, et al. Clinics (São Paulo, 
Brazil). 2007;62:47-54. DOI: 10.1590/
S1807-59322007000100008
[21] Sharma BK, Santana IA, Wood EC, 
Walt RP, Pereira M, Noone P, et al. 
Intragastric bacterial activity and 
nitrosation before, during, and after 
treatment with omeprazole. British 
Medical Journal. 1984;289:717-719. DOI: 
10.1136/bmj.289.6447.717
[22] Adamsson I, Nord CE, Lundquist P, 
Sjöstedt S, Edlund C. Comparative effects 
of omeprazole, amoxycillin plus 
metronidazole versus omeprazole, 
clarithromycin plus metronidazole 
on the oral, gastric and intestinal 
microflora in Helicobacter pylori-infected 
patients. The Journal of Antimicrobial 
Chemotherapy. 1999;44:629-640. DOI: 
10.1093/jac/44.5.629
[23] Sjöstedt S, Heimdahl A, Kager L, 
Nord CE. Microbial colonization of the 
oropharynx, esophagus and stomach in 
patients with gastric diseases. European 
Journal of Clinical Microbiology. 
1985;4:49-51. DOI: 10.1007/BF02148660
[24] Janda JM, Abbott SL. 16S rRNA gene 
sequencing for bacterial identification 
in the diagnostic laboratory: Pluses, 
perils, and pitfalls. Journal of Clinical 
Microbiology. 2007;45(9):2761-2764. 
DOI: 10.1128/JCM.01228-07
[25] Langendijk PS, Schut F, 
Jansen GJ, Raangs GC, Kamphuis GR, 
Wilkinson MH, et al. Quantitative 
fluorescence in situ hybridization of 
Bifidobacterium spp. with genus-specific 
16S rRNAtargeted probes and its 
application in fecal samples. Applied 
and Environmental Microbiology. 
1995;61:3069-3075
[26] Aebischer T, Fischer A, Walduck A, 
Schlötelburg C, Lindig M, Schreiber S, 
et al. Vaccination prevents Helicobacter 
pylori-induced alterations of the gastric 
flora in mice. FEMS Immunology and 
Medical Microbiology. 2006;46: 
221-229. DOI: 10.1111/rp10.1016-j.
femsim.2004.05.008
[27] Lertpiriyapong K, Whary MT, 
Muthupalani S, Lofgren JL, 
Gamazon ER, Feng Y, et al. Gastric 
colonisation with a restricted commensal 
microbiota replicates the promotion of 
neoplastic lesions by diverse intestinal 
microbiota in the Helicobacter pylori 
INS-GAS mouse model of gastric 
carcinogenesis. Gut. 2013;63:54-63. DOI: 
10.1136/gutjnl-2013-305178
[28] Heilig HG, Zoetendal EG, 
Vaughan EE, Marteau P, Akkermans AD, 
13
Gastric Microbiota: Between Health and Disease
DOI: http://dx.doi.org/10.5772/intechopen.86926
de Vos WM. Molecular diversity of 
Lactobacillus spp. and other lactic acid 
bacteria in the human intestine as 
determined by specific amplification 
of 16S ribosomal DNA. Applied 
and Environmental Microbiology. 
2002;68:114-123. DOI: 10.1128/
AEM.68.1.114-123.2002
[29] Monstein HJ, Tiveljung A, Kraft CH, 
Borch K, Jonasson J. Profiling of 
bacterial flora in gastric biopsies from 
patients with Helicobacter pylori-
associated gastritis and histologically 
normal control individuals by 
temperature gradient gel electrophoresis 
and 16SrDNA sequence analysis. Journal 
of Medical Microbiology. 2000;49:817-
822. DOI: 10.1099/0022-1317-49-9-817
[30] Dicksved J, Lindberg M, 
Rosenquist M, Enroth H, Jansson JK, 
Engstrand L. Molecular characterization 
of the stomach microbiota in patients with 
gastric cancer and in controls. Journal of 
Medical Microbiology. 2009;58:509-516. 
DOI: 10.1099/jmm.0.007302-0
[31] Rolig AS, Cech C, Ahler E, 
Carter JE, Ottemann KM. The degree 
of Helicobacter pylori-triggered 
inflammation is manipulated by 
preinfection host microbiota. Infection 
and Immunity. 2013;81:1382-1389. DOI: 
10.1128/IAI.00044-13
[32] Lofgren JL, Whary MT, Ge Z, 
Muthupalani S, et al. Lack of commensal 
flora in Helicobacter pylori-infected 
INS-GAS mice reduces gastritis and 
delays intraepithelial neoplasia. 
Gastroenterology. 2011;140:210-220. 
DOI: 10.1053/j.gastro.2010.09.048
[33] Sheh A, Fox JG. The role of 
the gastrointestinal microbiome in 
Helicobacter pylori pathogenesis. Gut 
Microbes. 2013;4(6):505-531. DOI: 
10.4161/gmic.26205
[34] Andersson AF, Lindberg M, 
Jakobsson H, Bäckhed F, Nyrén P, 
Engstrand L. Comparative analysis 
of human gut microbiota by 
barcoded pyrosequencing. PLoS One. 
2008;3:e2836. DOI: 10.1371/journal.
pone.0002836
[35] Li XX, Wong GL, To KF, Wong VW, 
Lai LH, Chow DK, et al. Bacterial 
microbiota profiling in gastritis without 
Helicobacter pylori infection or non-
steroidal anti-inflammatory drug use. 
PLoS One. 2009;4:e7985. DOI: 10.1371/
journal.pone.0007985
[36] Stearns JC, Lynch MD, 
Senadheera DB, Tenenbaum HC, 
Goldberg MB, Cvitkovitch DG, et al. 
Bacterial biogeography of the human 
digestive tract. Scientific Reports. 
2011;1:170. DOI: 10.1038/srep00170
[37] Osaki T, Matsuki T, Asahara T, 
Zaman C, Hanawa T, Yonezawa H, et al. 
Comparative analysis of gastric bacterial 
microbiota in Mongolian gerbils after 
long-term infection with Helicobacter 
pylori. Microbial Pathogenesis. 
2012;53(1):12-18
[38] Tan MP, Kaparakis M, Galic M, 
Pedersen J, Pearse M, Wijburg OL, et al. 
Chronic Helicobacter pylori infection 
does dot significantly alter the 
microbiota of the murine stomach. 
Applied and Environmental 
Microbiology. 2007;73(3):1010-1013
[39] Maldonado-Contreras A, 
Goldfarb KC, Godoy-Vitorino F, et al. 
Structure of the human gastric bacterial 
community in relation to Helicobacter 
pylori status. The ISME Journal. 
2010;5(4):574-579. DOI: 10.1038/
ismej.2010.149
[40] Lemke LB, Ge Z, Whary MT, et al. 
Concurrent Helicobacter bilis infection in 
C57BL/6 mice attenuates proinflammatory 
H. pylori-induced gastric pathology. 
Infection and Immunity. 2009;77(5): 
2147-2158. DOI: 10.1128/IAI.01395-08
[41] Ge Z, Feng Y, Muthupalani S, 
et al. Infection and Immunity. 
Gastrointestinal Stomas
14
2011;79(10):3861-3871. DOI: 10.1128/
IAI.05357-11
[42] Nagai S, Mimuro H, Yamada T, et al. 
Role of Peyer's patches in the induction 
of Helicobacter pylori-induced gastritis. 
Proceedings of the National Academy 
of Sciences of the United States of 
America. 2007;104(21):8971-8976. DOI: 
10.1073/pnas.0609014104
[43] Draser BS, Shiner M, McLeod GM. 
Studies of the intestinal flora 1. The 
bacterial flora of the gastrointestinal 
tract in healthy and achlorhydric 
patients. Gastroenterology. 
1969;56:71-79
[44] Milton-Thompson GJ, Lightfoot NF, 
Ahmet Z, et al. Intragastric acidity, 
bacteria, nitrite, and N-nitroso 
compounds before, during, and 
after cimetidine treatment. Lancet. 
1982;1(8281):1091-1095
[45] Goldsmith JR, Sartor RB. The 
role of diet on intestinal microbiota 
metabolism: Downstream impacts on 
host immune function and health, and 
therapeutic implications. Journal of 
Gastroenterology. 2014;49(5):785-798. 
DOI: 10.1007/s00535-014-0953-z
[46] Korpela K, Flint HJ, Johnstone AM, 
et al. Gut microbiota signatures 
predict host and microbiota 
responses to dietary interventions 
in obese individuals. PLoS One. 
2014;9(6):e90702. DOI: 10.1371/
journal.pone.0090702
[47] David LA, Maurice CF, 
Carmody RN, et al. Diet rapidly 
and reproducibly alters the 
human gut microbiome. Nature. 
2013;505(7484):559-563. DOI: 10.1038/
nature12820
[48] Chan YK, Estaki M, Gibson DL. 
Clinical consequences of diet-induced 
dysbiosis. Annals of Nutrition and 
Metabolism. 2013;63(suppl 2):28-40. 
DOI: 10.1159/000354902
[49] Fan W, Huo G, Li X, et al. Impact of 
diet in shaping gut microbiota revealed 
by a comparative study in infants 
during the six months of life. Journal 
of Microbiology and Biotechnology. 
2014;24(2):133-143
[50] Wu GD, Chen J, Hoffmann C, et al. 
Linking long-term dietary patterns with 
gut microbial enterotypes. Science. 
2011;334:105-108. DOI: 10.1126/science. 
1208344
[51] Sanduleanu S, Jonkers D, De 
Bruine A, Hameeteman W, 
Stockbrügger RW. Non-Helicobacter 
pylori bacterial flora during acid-
suppressive therapy: Differential 
findings in gastric juice and gastric 
mucosa. Alimentary Pharmacology & 
Therapeutics. 2001;15(3):379-388. DOI: 
10.1046/j.1365-2036.2001.00888.x
[52] Williams C, McColl KEL. Review 
article: Proton pump inhibitors 
and bacterial overgrowth. 
Alimentary Pharmacology & 
Therapeutics. 2006;23(1):3-10. DOI: 
10.1111/j.1365-2036.2006.02707.x
[53] Meuwissen SG, Craanen ME, 
Kuipers EJ. Gastric mucosal 
morphological consequences of 
acid suppression: A balanced view. 
Best practice & research. Clinical 
Gastroenterology. 2001;15(3):497-510. 
DOI: 10.1053/bega.2001.0189
[54] Mason KL, Erb Downward JR, 
Falkowski NR, Young VB, Kao JY, 
Huffnagle GB. Interplay between the 
gastric bacterial microbiota and 
Candida albicans during postantibiotic 
recolonization and gastritis. Infection 
and Immunity. 2012;80(1):150-158. 
DOI: 10.1128/IAI.05162-11
[55] Zhang X, Zhang J, Lin Y, 
Xu K, Li N, Chen H, et al. Analysis 
of the relationship between invasive 
capability of Helicobacter pylori and 
gastroduodenal diseases. Journal 
of Medical Microbiology. 2015 
15
Gastric Microbiota: Between Health and Disease
DOI: http://dx.doi.org/10.5772/intechopen.86926
May;64(Pt 5):498-506. DOI: 10.1099/
jmm.0.000049
[56] Blaser MJ, Atherton JC. Helicobacter 
pylori persistence: Biology and disease. 
The Journal of Clinical Investigation. 
2004;113(3):321-333. DOI: 10.1172/
JCI20925
[57] Correa P, Piazuelo MB. 
Helicobacter pylori infection and 
gastric adenocarcinoma. US 
Gastroenterology and Hepatology 
Review. 2011;7(1):59-64
[58] Ford AC, Gurusamy KS, Delaney B, 
Forman D, Moayyedi P. Eradication 
therapy for peptic ulcer disease in 
Helicobacter pylori-positive people. 
Cochrane Database of Systematic 
Reviews. 2016;4:CD003840. DOI: 
10.1002/14651858.CD003840.pub5
[59] Engstrand L, Lindberg M. 
Helicobacter pylori and the gastric 
microbiota. Best Practice & Research. 
Clinical Gastroenterology. 2013;27: 
39-45. DOI: 10.1016/j.bpg.2013.03.016
[60] Khosravi Y, Dieye Y, Poh BH, 
et al. Culturable bacterial microbiota 
of the stomach of Helicobacter pylori 
positive and negative gastric disease 
patients. The Scientific World 
Journal. 2014;2014:610421. DOI: 
10.1155/2014/610421
[61] Karimi P, Islami F, 
Anandasabapathy S, Freedman ND, 
Kamangar F. Gastric cancer: Descriptive 
epidemiology, risk factors, screening, 
and prevention. Cancer Epidemiology, 
Biomarkers & Prevention. 
2014;23(5):700-713. DOI: 10.1158/1055-
9965.EPI-13-1057
[62] Forman D, Newell DG, Fullerton F, 
et al. Association between infection 
with Helicobacter pylori and risk 
of gastric cancer: Evidence from 
a prospective investigation. BMJ. 
1991;302(6788):1302-1305
[63] Nomura A, Stemmermann GN, 
Chyou PH, Kato I, Perez-Perez GI, 
Blaser MJ. Helicobacter pylori infection 
and gastric carcinoma among 
Japanese Americans in Hawaii. The 
New England Journal of Medicine. 
1991;325(16):1132-1136. DOI: 10.1056/
NEJM199110173251604
[64] Hsu PI, Lai KH, Hsu PN, et al. 
Helicobacter pylori infection and 
the risk of gastric malignancy. The 
American Journal of Gastroenterology. 
2007;102(4):725-730. DOI: 
10.1111/j.1572-0241.2006.01109.x
[65] Malfertheiner P, Megraud F, 
O’Morain CA, et al. Management of 
Helicobacter pylori infection--the 
Maastricht IV/ Florence consensus 
report. Gut. 2012;61(5):646-664. DOI: 
10.1136/gutjnl-2012-302084
[66] Sheu BS, Wu MS, Chiu CT, et al. 
Consensus on the clinical management, 
screening-to-treat, and surveillance of 
Helicobacter pylori infection to improve 
gastric cancer control on a nationwide 
scale. Helicobacter. 2017;22(3):e12368. 
DOI: 10.1111/hel.12368
[67] Lee CW, Rickman B, Rogers AB, 
et al. Combination of sulindac and 
antimicrobial eradication of Helicobacter 
pylori prevents progression of 
gastric cancer in hypergastrinemic 
INS-GAS mice. Cancer Research. 
2009;69(20):8166-8174. DOI: 
10.1158/0008-5472.CAN-08-3856
[68] Wang L, Zhou J, Xin Y, Geng C, 
Tian Z, Yu X, et al. Bacterial overgrowth 
and diversification of microbiota 
in gastric cancer. European Journal 
of Gastroenterology & Hepatology. 
2016;28(3):261-266. DOI: 10.1097/
MEG.0000000000000542
[69] Eun CS, Kim BK, Han DS, Kim SY, 
Kim KM, Choi BY, et al. Differences in 
gastric mucosal microbiota profiling in 
patients with chronic gastritis, intestinal 
metaplasia, and gastric cancer using 
Gastrointestinal Stomas
16
pyrosequencing methods. Helicobacter. 
2014;19:407-416. DOI: 10.1111/hel.12145
[70] Walker MM, Talley NJ. Review 
article: Bacteria and pathogenesis of 
disease in the upper gastrointestinal 
tract–beyond the era of Helicobacter 
pylori. Alimentary Pharmacology & 
Therapeutics. 2014;39(8):767-779. DOI: 
10.1111/apt.12666
[71] Alarcon T, Lorca L, Pereze-Perez G. 
Impact of microbiota and gastric disease 
development by Helicobacter pylori. 
Current Topics in Microbiology and 
Immunology. 2017;400:253-275. DOI: 
10.1007/978-3-319-50520-6_11
[72] Ianiro G, Molina-Infante J, 
Gasbarrini A. Gastric microbiota. 
Helicobacter. 2015;20(Suppl. 1):68-71. 
DOI: 10.1111/hel.12260
[73] Giamarellos-Bourboulis E, 
Tang J, Pyleris E, Pistiki A, 
Barbatzas C, Brown J, et al. Molecular 
assessment of differences in the 
duodenal microbiome in subjects with 
irritable bowel syndrome. Scandinavian 
Journal of Gastroenterology. 
2015;50(9):1076-1087. DOI: 
10.3109/00365521.2015.1027261
[74] Zhang Y, Hoffmeister M, Weck MN, 
Chang-Claude J, Brenner H. Helicobacter 
pylori infection and colorectal cancer 
risk: Evidence from a large population-
based case-control study in Germany. 
American Journal of Epidemiology. 
2012;175(5):441-450. DOI: 10.1093/aje/
kwr331
[75] Kim TJ, Kim ER, Chang DK, 
et al. Helicobacter pylori infection is 
an independent risk factor of early 
and advanced colorectal neoplasm. 
Helicobacter. 2017;22(3):e12377. DOI: 
10.1111/hel.12377
[76] Lin R, Zhou L, Zhang J, Wang B. 
Abnormal intestinal permeability and 
microbiota in patients with autoimmune 
hepatitis. International Journal of 
Clinical and Experimental Pathology. 
2015;8(5):5153-5160
[77] Franchini M, Vescovi PP, 
Garofano M, Veneri D. Helicobacter 
pylori-associated idiopathic 
thrombocytopenic purpura: A narrative 
review. Seminars in Thrombosis and 
Hemostasis. 2012;38(5):463-468. DOI: 
10.1055/s-0032-1305781
[78] Cardenas VM, Mulla ZD, 
Ortiz M, Graham DY. Iron deficiency 
and Helicobacter pylori infection in the 
United States. American Journal of 
Epidemiology. 2006;163(2):127-134. 
DOI: 10.1093/aje/kwj018
[79] Nam SY, Park BJ, Ryu KH, 
Nam JH. Effect of Helicobacter pylori 
eradication on the regression of gastric 
polyps in National Cancer Screening 
Program. The Korean Journal of Internal 
Medicine. 2017;33(3):506-511. DOI: 
10.3904/kjim.2016.286
[80] Suwarnalata G, Tan AH, Isa H, 
et al. Augmentation of autoantibodies 
by Helicobacter pylori in Parkinson's 
disease patients may be linked 
to greater severity. PLoS One. 
2016;11(4):e0153725. DOI: 10.1371/
journal.pone.0153725
[81] Wang F, Liu J, Lv Z. Association 
of Helicobacter pylori infection 
with diabetes mellitus and diabetic 
nephropathy: A meta-analysis of 
39 studies involving more than 
20,000 participants. Scandinavian 
Journal of Infectious Diseases. 
2013;45(12):930-938. DOI: 
10.3109/00365548.2013.844351
